Plain-English translation of NCT06205056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new HIV prevention vaccine called Ad26.Mos4.HIV combined with CH505 TF chTrimer. Researchers want to see if this medication is safe, well tolerated, and can trigger the immune system to protect against HIV. The study will enroll 78 healthy volunteers and follow them for up to 18 months.
Currently, there is no vaccine that prevents HIV infection. This medication represents a new approach designed to mimic how the virus behaves in the body, potentially training the immune system to recognize and fight it before infection occurs.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive injections of the vaccine or placebo (salt water) into the thigh muscle on specific dates over several months. You may receive between 2 and 4 injections depending on which study group you are assigned to. Throughout the 18-month study, you will have regular clinic visits for blood tests, physical exams, and check-ins to monitor how you are doing and whether you experience any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Uganda